NeoGenomics (NEO) director adds 23,077 shares through RSU vesting
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
NeoGenomics Inc. director Neil Gunn reported compensation-related equity activity. On 2026-06-01, 23,077 restricted stock units vested and were exercised into an equal number of common shares at $0.00 per share, bringing his direct common stock holdings to 51,177.31 shares.
Gunn also received new awards of 15,970 restricted stock units and 11,069 stock options with an exercise price of $10.52 per share, exercisable from 2027-06-01 and expiring on 2036-06-01. Existing stock options with exercise prices ranging from $7.28 to $14.82 and expirations from 2033-08-10 to 2035-06-01 remain outstanding.
Positive
- None.
Negative
- None.
Insider Trade Summary
23,077 shares exercised/converted
Mixed
7 txns
Insider
Gunn Neil
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 23,077 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 11,069 | $0.00 | -- |
| Grant/Award | Restricted Stock Unit | 15,970 | $0.00 | -- |
| Exercise | Common Stock | 23,077 | $0.00 | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Unit — 0 shares (Direct, null);
Stock Option (Right to Buy) — 11,069 shares (Direct, null);
Common Stock — 51,177.31 shares (Direct, null)
Footnotes (1)
- Reflects the release of restricted stock units that were previously reported on a Form 4. Once vested, the shares of common stock are not subject to expiration.
Key Figures
RSUs vested into common stock: 23,077 shares
Common stock held after transactions: 51,177.31 shares
New RSU grant: 15,970 units
+4 more
7 metrics
RSUs vested into common stock
23,077 shares
Restricted stock units exercised into common shares on 2026-06-01
Common stock held after transactions
51,177.31 shares
Direct common stock ownership following Form 4 transactions
New RSU grant
15,970 units
Restricted Stock Units granted on 2026-06-01, underlying common stock
New stock option grant
11,069 options at $10.52
Stock Option (Right to Buy) exercisable 2027-06-01, expires 2036-06-01
Outstanding options @ $7.28
16,107 underlying shares
Stock options with $7.28 exercise price expiring 2035-06-01
Outstanding options @ $13.71
8,672 underlying shares
Stock options with $13.71 exercise price expiring 2034-06-01
Outstanding options @ $14.82
8,353 underlying shares
Stock options with $14.82 exercise price expiring 2033-08-10
Key Terms
Restricted Stock Unit, Stock Option (Right to Buy), derivative security, exercise price, +1 more
5 terms
Restricted Stock Unit financial
"security_title: "Restricted Stock Unit" for equity awards and vesting"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" describing option grants"
derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
exercise price financial
"conversion_or_exercise_price fields such as "7.2800" and "10.5200""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Form 4 regulatory
"Previously reported on a Form 4 in the footnote on RSU release"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
What insider transactions did Neil Gunn report at NeoGenomics (NEO)?
Neil Gunn reported equity compensation activity, not open-market trades. 23,077 restricted stock units vested into common shares, and he received new grants of 15,970 restricted stock units plus 11,069 stock options. These changes reflect updated holdings and awards rather than market purchases or sales.
What new equity awards did Neil Gunn receive from NeoGenomics (NEO)?
Neil Gunn received 15,970 restricted stock units and 11,069 stock options as new equity awards. The options have an exercise price of $10.52 per share, become exercisable on June 1, 2027, and expire on June 1, 2036, aligning with typical long-term director compensation structures.
What stock options does Neil Gunn hold in NeoGenomics (NEO) after this filing?
After this filing, Neil Gunn holds several option grants. These include options over 16,107 shares at $7.28, 8,672 shares at $13.71, 8,353 shares at $14.82, and a new grant for 11,069 shares at $10.52, with expirations between August 2033 and June 2036.